Aripiprazole Tablet
Product Images NDC 71335-1682

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 71335-1682). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure4 (Aripiprazole Fig4)

A chart titled 'Aripiprazole Fold Change and 90% CI' displaying pharmacokinetic comparisons of Aripiprazole in various special populations, including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels (mild, moderate, severe), and severe renal impairment. The graph shows fold changes relative to a reference along the x-axis, with AUC and Cmax parameters plotted on the y-axis for each subgroup.*

FDA Label Image

Figure5 (Aripiprazole Fig5)

A pharmacokinetic chart showing fold changes and 90% confidence intervals for dehydro-aripiprazole under various conditions, including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis represents change relative to reference, and the y-axis lists the conditions compared with reference groups for AUC and Cmax values.*

FDA Label Image

Structure (Aripiprazole Struct)

Chemical structure of Aripiprazole, showing the molecular arrangement of atoms including chlorine-substituted aromatic rings, a piperazine moiety, an ether linkage, and a quinolinone ring system.*

FDA Label Image

Aripiprazole_fig_01 (Aripiprazole Fig 01)

A scatter plot chart titled 'Effect of Other Drugs on Aripiprazole' displaying fold changes and 90% confidence intervals for pharmacokinetic parameters AUC and Cmax. The chart compares the effects of various inhibitors, inducers, and other drugs relative to a reference without interacting drugs.*

FDA Label Image

Aripiprazole_fig_02 (Aripiprazole Fig 02)

A plot showing the effect of various drugs on the pharmacokinetics of Aripiprazole, measured as fold change and 90% confidence intervals. The x-axis represents the change relative to the reference without interacting drug, ranging from 0 to 3. Drugs listed include CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blockers famotidine, and others like valproate, lithium, and lorazepam.*

FDA Label Image

Aripiprazole_fig_03 (Aripiprazole Fig 03)

A forest plot chart titled 'Effect of Aripiprazole on other Drugs' showing fold change and 90% confidence intervals for various drugs and enzymes. The x-axis represents change relative to reference (without interacting drug), ranging from 0.5 to 3.0. The y-axis lists drugs and enzymes like CYP2D6 substrates (dextromethorphan), CYP2C9 substrates (warfarin), omeprazole, valproate, lithium, lorazepam, venlafaxine, escitalopram, and others, with corresponding pharmacokinetic measures (AUC, Cmax, DMDRP, INR). Data points indicate the effect of aripiprazole on these drugs' pharmacokinetics.*

FDA Label Image

Figure6 (Aripiprazole Fig 06)

A Kaplan-Meier survival curve comparing the proportion of subjects with relapse over time between Aripiprazole and placebo groups. The x-axis shows days since randomization, with the number of subjects at risk at various intervals. The y-axis indicates the proportion experiencing relapse. Aripiprazole is represented by a solid blue line, and placebo by a dashed red line.*

FDA Label Image

Aripiprazole_fig_07 (Aripiprazole Fig 07)

A Kaplan-Meier curve chart comparing the proportion with relapse over days from randomization between two groups: Aripiprazole (blue solid line) and Placebo (red dashed line). The x-axis shows days from randomization up to 182 days, and the y-axis shows the proportion with relapse from 0 to 1. Below the x-axis is a table indicating the decreasing number of subjects at risk over time for both groups.*

FDA Label Image

Aripiprazole_fig_08 (Aripiprazole Fig 08)

A Kaplan-Meier survival curve chart showing the proportion with relapse over 364 days from randomization, comparing Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis indicates the proportion with relapse. The chart includes a risk table showing the number of subjects at risk for each treatment at various time points.*

FDA Label Image

Label Image (Lbl713351682)

Label for Aripiprazole 2 mg tablet, an oral human prescription drug packaged by Bryant Ranch Prepack in Burbank, CA. The label shows this product is comparable to Abilify 2 mg Tablet by Ajanta Pharma Limited. It specifies storage conditions at 20°-25°C and includes a barcode, lot number 1523487, and NDC 71335-1682-1. The label also contains warnings to keep drugs out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.